Drugs / SAR439281
last change Nov 2017 re-read 3 minutes ago

SAR439281

Developed for
breast cancer
Investigated by
Sanofi

Trials 1

201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02664103 Jan 2016 → Nov 2017 breast cancer Sanofi Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SAR439281 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02664103 ↗
Route Oral “Route of administration: Oral” NCT02664103 ↗